PAH-CHD predominantly Lt-Rt shunt with borderline PVR and ES
Completed
- Conditions
- Data of outcomes in patients who had PAH-CHD (confirmed by dignostic cardiac catheterization) with borderline pulmonary vascular resistance (PVR) and recieved directed targeted therapy prior to surgicPulmonary arterial hypertension, Congenital heart disease, treat and repair
- Registration Number
- TCTR20200420004
- Lead Sponsor
- Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 432
Inclusion Criteria
1.Patients who underwent cardiac catheterization to assess hemodynamic data or transcatheter closure of the defects in Siriraj Hospital between January 1st, 1995 and December 31st, 2021
2.All patients who had evidence of PAH-CHD on the cardiac catheterization including mPAP >20 mmHg, PAWP < 15 mmHg and calculated PVR > 3 WU based on a current definition of PAH
3.Patients who were classified in Eisenmenger syndrome and PAH-CHD with prevalent left to right shunt
Exclusion Criteria
1.Patients who had age < 3 months,
2.Patients with single ventricle following surgery
3.Patients who were classified in PAH with small defect and PAH following defect correction
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival rate/mortality End of 2023 Survival rate
- Secondary Outcome Measures
Name Time Method WHO Functional class end of 2023 Declined of functional class to III-IV